• Daniel White

    Daniel H. White

    President and Chief Executive Officer

    Mr. White is a founder of our company and has served as President and Chief Executive Officer and as a member of our board of directors since our inception in May 2011. From 2008 to 2011, Mr. White served as Executive Director, Global Corporate Development, for Stiefel Laboratories, Inc., a dermatology pharmaceutical company acquired by GlaxoSmithKline in 2009. From 2007 to 2008, he co-founded and served as President and Chief Executive Officer of Percept BioScience, Inc., a biotechnology company. In 2003, Mr. White co-founded, and until 2007 served as Vice President of Finance and Corporate Development of Alimera Sciences, Inc., a biopharmaceutical company focused on ophthalmology. He was Head of Business Development and Licensing for CIBA Vision, a Novartis company, and Director of Licensing and Business Development for AAIPharma. Mr. White holds a Master of Business Administration from Wake Forest University and a Bachelor of Science in Molecular Biology from Auburn University.
    • Charles Deignan

      Charles A. Deignan

      Chief Financial Officer

      Mr. Deignan has served as our Chief Financial Officer since January 2012. From 2009 to December 2011, Mr. Deignan was Vice President of Finance and Administration for Salutria Pharmaceuticals. From 1999 to 2009, Mr. Deignan served in a number of roles with AtheroGenics, Inc., a publicly held biopharmaceutical company, including as Vice President of Finance and Administration. His career has included management positions at AAIPharma, Inc., and Schering-Plough. Mr. Deignan received his Bachelor of Science in Business Administration from Boston University.
      • Glenn Noronha, Ph.D.

        Glenn Noronha, Ph.D.

        Executive Vice President, Research and Development

        Dr. Noronha was promoted to Chief Scientific Officer in August 2016 after having served as our Executive Vice President, Research and Development since August 2013. Dr. Noronha plays a critical role in all strategic, developmental and regulatory efforts at Clearside. From 2012 to 2013, he served as Vice President, Research and Development, at Sucampo Pharma Americas, LLC. From 2011 to 2012, Dr. Noronha was Chief Scientific Officer for JW Theriac, Inc., a pharmaceutical company focused on new drug research and development in oncology. From 2008 to 2011, Dr. Noronha was Global Project Lead for developmental efforts in retinal diseases at Alcon Laboratories, Inc., a Novartis company. From 2002 to 2008, Dr. Noronha held several positions with increasing levels of leadership and responsibility at TargeGen, Inc., a pharmaceutical company, including as co-lead for its ophthalmology programs. Dr. Noronha received his education and training in Chicago and Irvine.
        • Rafael Andino

          Rafael V. Andino

          Vice President, Engineering and Manufacturing

          Mr. Andino has served as our Vice President, Engineering and Manufacturing since February 2013. June He has also served as Adjunct Professor of Biomedical Engineering at the Georgia Institute of Technology since June 2013. From January 2009 to February 2013, he was Director of Research and Development for Bard Medical, a division of C.R. Bard, Inc., a publicly traded company. In 1999, Mr. Andino founded, and until 2008 served as President and Chief Executive Officer of Biofisica, Inc., a biotechnology company that developed technology to expedite wound healing and regeneration of connective tissue in humans. Prior to founding Biofisica, from 1995 to 2005 Mr. Andino was a Research and Development Director and Senior Project Manager for CIBA Vision, a Novartis company. He has also worked for the global technology companies E.I. Dupont de Nemours, General Electric, and IBM. Mr. Andino received his Bachelor of Science in Mechanical Engineering from the Georgia Institute of Technology, a Master of Science in Biomedical Engineering from the University of Alabama at Birmingham and a Master of Business Administration from Mercer University.
          • Richard L. Beckman

            Richard L. Beckman, MD

            Chief Medical Officer

            Dr. Beckman is a board certified ophthalmologist who brings 13 years of clinical practice experience and over 20 years of corporate executive and consultancy experience within the global ophthalmic industry to Clearside. Prior to joining our company, Dr. Beckman managed a successful pharmaceutical and medical device industry consulting firm that served a broad range of companies. Previously, he held the position of Chief Medical Officer and General Manager of the Ocular and Novel Drug Delivery Systems business unit at Unilife Corporation. He has also held senior leadership roles with Ophthotech Pharmaceuticals, Neurotech Pharmaceuticals, Alcon Laboratories, Lux Pharmaceuticals and Becton-Dickinson. Dr. Beckman received his medical degree from the University of Michigan, and practiced as a glaucoma specialist for three years in academic practice at North Shore University Hospital-Cornell University Medical College, and for ten years in private practice following an ophthalmology residency at Henry Ford Hospital and a Glaucoma Fellowship at Harvard University.
            • Jennifer Kissner

              Jennifer Ph.D. Kissner

              Vice President, Clinical Development

              Dr. Kissner was promoted to Vice President, Clinical Development in August 2016 after having served as our Senior Director of Development since August 2014. Dr. Kissner has 14 years of clinical development experience, 9 of which have been with entities addressing sight-threatening diseases in positions at ophthalmology companies such as Alcon Laboratories, Inc., a Novartis company and Acucela, Inc. Dr. Kissner received her PhD and conducted her post-doctoral research at Emory University before spending five years at Vanderbilt University addressing infectious diseases while holding several positions of increasing responsibility in the Department of Pediatrics and developing a centralized clinical research office.
              • Rick McElheny

                Rick McElheny

                Vice President, Business Development

                Mr. McElheny has served as our Vice President, Corporate Development since November 2016. From 2011 to 2015, Mr. McElheny Founded and served as Vice President Corporate Development and Supply Chain for Vidara Therapeutics, a specialty pharmaceutical company focused on developing and marketing orphan drugs. From 2005 to 2011, he worked in various roles at Meda Pharmaceuticals including business development, market research, and supply chain management. He has also worked in various supply chain roles at Johnson and Johnson and Schering Plough. Mr. McElheny holds a Master of Business Administration degree from New York University and Bachelor of Science degrees in Environmental Resource Management and Business Management from Penn State University.

                Let’s get the conversation going

                Questions? We’d love to hear from you.


                Investor Menu